UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000034904
Receipt number R000039753
Scientific Title Sucroferric oxyhydroxide Guanules Questionnaire survey
Date of disclosure of the study information 2018/11/20
Last modified on 2019/11/18 11:10:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Sucroferric oxyhydroxide Guanules Questionnaire survey

Acronym

Sucroferric oxyhydroxide Guanules Questionnaire survey

Scientific Title

Sucroferric oxyhydroxide Guanules Questionnaire survey

Scientific Title:Acronym

Sucroferric oxyhydroxide Guanules Questionnaire survey

Region

Japan


Condition

Condition

Improvement of hyperphosphatemia in dialysis patients

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Do a survey of Administration feeling of Sucroferric oxyhydroxide Guanules

Basic objectives2

Others

Basic objectives -Others

Administration feeling

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Administration feeling

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Administered Sucroferric oxyhydroxide Guanules and hyperphosphatemia in dialysis patients
2)Patients can acquire written informed consent appropriately (excluding patients with dementia)

Key exclusion criteria

Pharmacist judged ineligible as subject of investigation

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Yoshiyuki
Middle name
Last name Inami

Organization

Qol Co.,Ltd.

Division name

Chubu Pharmacy Business Division

Zip code

450-6034

Address

1-1-4, Meieki, Nakamura-ku, Nagoya, Aichi, Japan

TEL

052-589-1389

Email

y-oikawa@apoplus.co.jp


Public contact

Name of contact person

1st name Yoshinobu
Middle name
Last name Oikawa

Organization

APO PLUS STATION CO., LTD.

Division name

CRO Division

Zip code

103-0027

Address

14-1 Nihonbashi2-chome, Chuo-ku, Tokyo, Japan

TEL

03-6386-9500

Homepage URL


Email

y-oikawa@apoplus.co.jp


Sponsor or person

Institute

Qol Co.,Ltd.

Institute

Department

Personal name



Funding Source

Organization

Kissei Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kitamachi Clinic Ethics Review Committee

Address

1-1-3, Kitamachi, kichijyoji, musasino-city, Tokyo, JAPAN

Tel

070-5011-8550

Email

shingo-namiki@j-smo.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

クオール薬局


Other administrative information

Date of disclosure of the study information

2018 Year 11 Month 20 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

https://www.iyaku.info/magazine/magazine_1.html

Number of participants that the trial has enrolled

75

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results

2019 Year 11 Month 10 Day

Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 10 Month 19 Day

Date of IRB

2018 Year 11 Month 20 Day

Anticipated trial start date

2018 Year 11 Month 21 Day

Last follow-up date

2019 Year 07 Month 26 Day

Date of closure to data entry

2019 Year 07 Month 29 Day

Date trial data considered complete

2019 Year 07 Month 29 Day

Date analysis concluded

2019 Year 07 Month 31 Day


Other

Other related information

Questionnaire survey


Management information

Registered date

2018 Year 11 Month 15 Day

Last modified on

2019 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039753


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name